Status | Study |
Recruiting |
Study Name: Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies Condition: Sickle Cell Disease Transfusion Dependent Alpha- or Beta- Thalassemia Date: 2014-06-27 Interventions: Drug: Reduced Toxicity Ablative Regimen |
Recruiting |
Study Name: BMT Abatacept for Non-Malignant Diseases Condition: Hurler Syndrome Fanconi Anemia Glanz Date: 2013-07-24 Interventions: Drug: Abatacept All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis |
Active, not recruiting |
Study Name: A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan Condition: Congenital Bleeding Disorder Glanzmann's Disease Date: 2013-05-31 Interventions: Drug: eptacog alfa (activated) Patients will be treated according to routine clinical practice at the di |
Completed |
Study Name: Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects Condition: Acquired Bleeding Disorder Acquired Haemophilia Congenital Date: 2012-03-21 Interventions: Drug: activated recombinant human factor VII One single dose administration, injected i.v. (into the vei |
Completed |
Study Name: Observational Registry of the Treatment of Glanzmann's Thrombasthenia Condition: Congenital Bleeding Disorder Glanzmann's Disease Date: 2011-10-07 Interventions: Drug: activated recombinant human factor VII A prospective, observational multi-national registry collec |
Suspended |
Study Name: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation Condition: Thalassemia Sickle Cell Disease Glan Date: 2010-09-15 Interventions: Drug: Alefacept 0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacep |
Completed |
Study Name: Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany Condition: Congenital Bleeding Disorder Congenital FVII Deficiency Date: 2008-06-11 Interventions: Drug: eptacog alfa (activated) A NON INTERVENTIONAL OBSERV |
Recruiting |
Study Name: The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders. Condition: Glanzmann Thrombasthenia Date: 2005-09-28 |